7月2日【立方招采通】标讯亮点包括工程建设、医疗药械、商务服务、设备采购等项目。其中：山姆会 员商店建设施工项目和南阳市第六人民医院医疗设备采购项目（第一批）可重点关注。 预算金额：318.00万元 项目概况：采购全数字化彩色多普勒超声诊断仪、全自动生化免疫流水线、全自动分枝杆菌培养监测仪 等21项设备 提交投标文件截止时间：2025年7月24日9时 郑州东沃管理有限公司发布山姆会员商店建设施工项目招标计划，计划招标时间为2025年7月，合同估 算价为2.5亿元；该工程监理项目同日启动招标，合同估算价为125万元。项目位于郑州市郑东新区如意 东路东、如意河东十街北，总用地面积29338.4平方米（约44.01亩）。其中商业用地21508.4平方米，总 建筑面积61600平方米。该地块于今年1月由郑州东沃管理有限公司以2.03亿元竞得；今年3月中国建筑 西南设计研究院成功中标该项目建筑方案设计。 南阳市第六人民医院医疗设备采购项目（第一批）资金来源为财政资金，采购内容为：全自动细菌鉴定 及药敏分析系统、全自动流式细胞仪、全自动细菌分散计数仪、全自动微生物培养系统、全自动医用 PCR检测系统等21套设备，包含医疗 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603387 证券简称：基蛋生物 公告编号：2025-022 基蛋生物科技股份有限公司关于2024年度暨2025年第一季度业绩网上说明会召开情况的公告 基蛋生物科技股份有限公司（以下简称"公司"）于2025年5月27日14:00-15:00在上证所信息网络有限公 司上证路演中心平台（以下简称"上证路演中心"）采用网络互动方式召开"基蛋生物2024年度暨2025年 第一季度业绩说明会"。关于本次业绩说明会的召开事项，公司已于2025年4月30日在《上海证券报》及 上海证券交易所网站上披露了《基蛋生物科技股份有限公司关于召开2024年度暨2025年第一季度业绩说 明会的公告》（公告编号：2025-013）。现将有关事项公告如下： 一、本次说明会召开情况 2025年5月27日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董事会秘书刘葱女士、公司独 立董事万遂人先生、公司独立董事鞠熀先先生、公司独立董事凌华女士出席了本次业绩 ...

Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]